sohonos Drug Patent Profile
✉ Email this page to a colleague
When do Sohonos patents expire, and when can generic versions of Sohonos launch?
Sohonos is a drug marketed by Ipsen and is included in one NDA. There are five patents protecting this drug.
This drug has fifty-three patent family members in twenty-two countries.
The generic ingredient in SOHONOS is palovarotene. One supplier is listed for this compound. Additional details are available on the palovarotene profile page.
DrugPatentWatch® Generic Entry Outlook for Sohonos
Sohonos will be eligible for patent challenges on August 16, 2027. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be August 16, 2030. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for sohonos?
- What are the global sales for sohonos?
- What is Average Wholesale Price for sohonos?
Summary for sohonos
International Patents: | 53 |
US Patents: | 5 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 51 |
Patent Applications: | 46 |
Drug Prices: | Drug price information for sohonos |
What excipients (inactive ingredients) are in sohonos? | sohonos excipients list |
DailyMed Link: | sohonos at DailyMed |
![sohonos drug patent expirations Drug patent expirations by year for sohonos](/p/graph/s/t/sohonos-patent-expirations.png)
![Drug Prices for sohonos](/p/graph/drug-price/sohonos.png)
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for sohonos
Generic Entry Date for sohonos*:
Constraining patent/regulatory exclusivity:
FOR THE REDUCTION IN VOLUME OF NEW HETEROTOPIC OSSIFICATION IN ADULTS AND PEDIATRIC PATIENTS AGED 8 YEARS AND OLDER FOR FEMALES AND 10 YEARS AND OLDER FOR MALES WITH FIBRODYSPLASIA OSSIFICANS PROGRESSIVA (FOP) NDA:
Dosage:
CAPSULE;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
US Patents and Regulatory Information for sohonos
sohonos is protected by five US patents and two FDA Regulatory Exclusivities.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of sohonos is ⤷ Sign Up.
This potential generic entry date is based on FOR THE REDUCTION IN VOLUME OF NEW HETEROTOPIC OSSIFICATION IN ADULTS AND PEDIATRIC PATIENTS AGED 8 YEARS AND OLDER FOR FEMALES AND 10 YEARS AND OLDER FOR MALES WITH FIBRODYSPLASIA OSSIFICANS PROGRESSIVA (FOP).
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting sohonos
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: REDUCTION OF HETEROTOPIC OSSIFICATION IN PATIENTS WITH FIBRODYSPLASIA (MYOSITIS) OSSIFICANS PROGRESSIVA
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: REDUCTION OF HETEROTOPIC OSSIFICATION IN PATIENTS WITH FIBRODYSPLASIA (MYOSITIS) OSSIFICANS PROGRESSIVA
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: REDUCTION OF HETEROTOPIC OSSIFICATION IN PATIENTS WITH FIBRODYSPLASIA (MYOSITIS) OSSIFICANS PROGRESSIVA
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: REDUCTION OF HETEROTOPIC OSSIFICATION IN PATIENTS WITH FIBRODYSPLASIA (MYOSITIS) OSSIFICANS PROGRESSIVA
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: REDUCTION OF HETEROTOPIC OSSIFICATION IN PATIENTS WITH FIBRODYSPLASIA (MYOSITIS) OSSIFICANS PROGRESSIVA
FDA Regulatory Exclusivity protecting sohonos
FOR THE REDUCTION IN VOLUME OF NEW HETEROTOPIC OSSIFICATION IN ADULTS AND PEDIATRIC PATIENTS AGED 8 YEARS AND OLDER FOR FEMALES AND 10 YEARS AND OLDER FOR MALES WITH FIBRODYSPLASIA OSSIFICANS PROGRESSIVA (FOP)
Exclusivity Expiration: ⤷ Sign Up
NEW CHEMICAL ENTITY
Exclusivity Expiration: ⤷ Sign Up
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Ipsen | SOHONOS | palovarotene | CAPSULE;ORAL | 215559-005 | Aug 16, 2023 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Ipsen | SOHONOS | palovarotene | CAPSULE;ORAL | 215559-004 | Aug 16, 2023 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Ipsen | SOHONOS | palovarotene | CAPSULE;ORAL | 215559-005 | Aug 16, 2023 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Ipsen | SOHONOS | palovarotene | CAPSULE;ORAL | 215559-005 | Aug 16, 2023 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Ipsen | SOHONOS | palovarotene | CAPSULE;ORAL | 215559-001 | Aug 16, 2023 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Ipsen | SOHONOS | palovarotene | CAPSULE;ORAL | 215559-003 | Aug 16, 2023 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Ipsen | SOHONOS | palovarotene | CAPSULE;ORAL | 215559-004 | Aug 16, 2023 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
EU/EMA Drug Approvals for sohonos
Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
---|---|---|---|---|---|---|---|---|---|
Ipsen Pharma | Sohonos | palovarotene | EMEA/H/C/004867 Treatment of fibrodysplasia ossificans progressiva. |
Refused | no | no | yes | 2023-07-17 | |
>Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
International Patents for sohonos
See the table below for patents covering sohonos around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
World Intellectual Property Organization (WIPO) | 2017210792 | ⤷ Sign Up | |
Colombia | 6680694 | Composición y método para la reparación y regeneración muscular | ⤷ Sign Up |
Denmark | 3721880 | ⤷ Sign Up | |
Eurasian Patent Organization | 026251 | СПОСОБ ВОССТАНОВЛЕНИЯ И РЕГЕНЕРАЦИИ МЫШЦ (METHOD FOR MUSCLE REPAIR AND REGENERATION) | ⤷ Sign Up |
Japan | 7023868 | ⤷ Sign Up | |
Chile | 2013000580 | Metodo de regeneracion o reparacion muscular que comprende administrar un antagonista del receptor de acido retinoico gama (rary); metodo para la induccion o estimulacion de diferenciacion miogenica de celulas madre; composicion que comprende celulas madre mesenquimales; composicion farmaceutica; kit. | ⤷ Sign Up |
South Africa | 201808102 | METHODS FOR TREATING HETEROTOPIC OSSIFICATION | ⤷ Sign Up |
>Country | >Patent Number | >Title | >Estimated Expiration |